The management of severe myasthenia gravis presents a continuing challenge to the physician. Even with the most careful adjustment of anticholinesterase medication the patient may become severely disabled. Thymectomy seems to offer real benefit to some of the carefully selected patients.
However, despite the careful employment of anticholinesterase medication and the improvement after some thymectomies, some patients still cannot be adequately controlled and become severely disabled and die.
In 1951 Torda and Wolff treated these refractory myasthenia patients with ACTH. They obtained a 'significant partial remission' after corticotropin therapy in 10 of 15 patients. They recognized, however, that a transient and sometimes severe exacerbation of weakness was apt to occur during the first days of treatment. One of their 15 patients died during such an exacerbation. Their report was directly contradicted by Grob and Harvey, who reported in 1952 that in none of their 10 patients was any increase in strength observed either during or after ACTH administration.
In subsequent years, however, there have been additional reports (Grob and Namba, 1966; Osserman and Genkins, 1966; von Reis, Liljestrand, and Matell, 1966) of remissions lasting three months or longer. Such remissions were more consistent after massive doses of ACTH. von Reis et al. (1966) , for example, gave 1,000 u. ACTH over a period of six to 12 days to 13 patients and obtained excellent results in 23 out of 33 courses of treatment.
Ample clinical experience has shown that massive doses of ACTH will often bring about a remission when myasthenia is otherwise refractory to medication. The reports have uniformly noted that initiation of treatment carries danger because of transient increase of weakness, and all have lamented the brevity of the remission which might 'This paper was read at the meeting of the Memphis Neurological Society, Memphis, Tennessee, 8 June, 1968. last only a few weeks. Unfortunately, this remission may be followed by another exacerbation. Osserman and Genkins in 1966 commented that in one of their patients 'clinical improvement . . . has been maintained by serial weekly and biweekly injections of corticotropin that are given on an out-patient basis. ' We have attempted to prolong remissions in our patients by continuing maintenance therapy and have been surprised by the favourable results. The present study relates our experience with the beneficial effect of massive doses of ACTH in five patients with refractory myasthenia gravis, and with maintenance therapy with ACTH in three patients for 16 to 23 months. CASE REPORTS CASE 1 A 24-year-old girl had myasthenia gravis, group III, according to the clinical classification of myasthenia gravis (Table I) . She had numerous crises requiring emergency tracheostomies and continuous respiratory assistance; eventually she was left with a permanent tracheostomy. Her disease was never adequately controlled on anticholinesterase medication, and for long periods she was scarcely able to survive. Neurological examination during this period showed bilateral ptosis with extemal ophthalmoplegia and bilateral facial paresis. The palate elevated very poorly and she was dysarthric. The strength of the muscles of the upper and lower extremities was grade 3 (Medical Research Council, 1942) . She was confined to her house because of her poor physical reserve. On 21 June 1965, she was started on a 10-day course of ACTH, receiving 100 u. per day intramuscularly for a total of 1,000 u. She began a dramatic improvement on 22 June 1965 without any prior worsening of her myasthenic symptoms. She did not require anticholinesterase medication during most of the three-month remission. Examination during this remission showed residual external ophthalmoplegia of the left eye except for downward gaze, but there were nearly normal movements of the right eye. There was no ptosis or facial paresis. The strength of her extremities had increased to greater than grade 4 and her exercise tolerance allowed her to assume nearly normal activities. 290 In summary, this young lady was totally disabled and frequently bedfast in spite of a thymectomy and intensive therapy with anticholinesterase medication. Intensive courses of ACTH were consistently followed by improvements in her strength, but these had been regularly followed by recurrences of the weakness until she was started on maintenance ACTH. With maintenance ACTH injections of 100 u. weekly her strength has remained improved; there has been no recurrence of the weakness for a period of 23 months. She continues to use Mestinon (pyridostigmine), 60 mg three to five times daily.
CASE 2 A 51-year-old Negro male had the onset of severe generalized and bulbar myasthenia gravis (group III) in December 1965. Despite the benefit derived from anticholinesterase medication he was always in moderate respiratory distress and often was confined to bed during the next nine months. His anticholinesterase medications were carefully regulated in the hospital. On what was considered optimal dosage of Mytelase (ambenonium) his neurological examination showed severe bilateral ptosis, inability to converge or to adduct either eye, and paresis of abduction resulting in nystagmoid jerks. He was unable to gaze either upward or downward. There was mild bilateral facial paresis. The strength of the proximal muscles of the upper extremities was grade 4 and that of the distal muscles was grade 3. The strength of the proximal muscles of the lower extremities was grade 3 and that of the distal muscles was grade 2. He went into a myasthenic crisis when one dose of his medication was skipped.
After nine months of fruitless efforts to control his myasthenia with anticholinesterase medication, he was given 1,040 u. weaker toward the end of this course of treatment, but the results of neurological examination were unchanged until the last day of injections, 11 March, when he became dyspnoeic and his dysphagia and dysarthria became worse. This exacerbation of his myasthenia lasted five days and he then had a remission lasting 40 days. During this period he was asymptomatic except for mild weakness of the ocular muscles.
His myasthenia recurred, and again was refractory to treatment with anticholinesterase medication. The neurological findings were essentially the same as they had been before the second course of ACTH. One thousand units ACTH were given over a period of 10 days beginning 19 May 1967. On the second day of injections he became very weak, dyspnoeic, and could not swallow, but this was followed promptly by a remission which lasted over two months. During this remission, as with the other remissions, he continued taking 60 to 90 mg Mestinon four times a day.
Early in September his symptoms were beginning to be troublesome once more. Examination at this time revealed almost complete external ophthalmoplegia; there was minimal lateral rectus movement bilaterally. He had bilateral ptosis and facial weakness, but no dysphagia. Although this did not represent so complete an exacerbation as he had previously suffered, we decided to offer another course of intensive therapy and follow it with maintenance ACTH treatment. On 11 September 1967, the fourth course of 1,000 u. was started. He developed generalized weakness of the extremities (grade 4) on the fourth, fifth, and sixth days of ACTH treatment, but by the seventh day this began to clear. There was then a rapid remission of all his symptoms; soon there was absolutely no paresis of any of the ocular or bulbar muscles.
After this fourth intensive course of ACTH he was maintained on 100 u. ACTH intramuscularly every week. There was no recurrence of any weakness, either subjectively or by examination, for the next three months. During December 1967 he developed a mild paresis of his left medial rectus muscle, along with a barely detectable ptosis on that side. This ptosis gradually disappeared, but a very mild paresis of the left medial rectus was still evident in January 1969.
In summary, this patient obtained complete remissions after each of three courses of intensive ACTH therapy. Each of these remissions was followed by another exacerbation within two months. After a fourth intensive course he was given weekly injections of ACTH, and the remissionhas beenmaintained continuously for 16 months. A course of 920 u. ACTH intramuscularly was given between 25 July 1967 and 3 August 1967. On the fourth day of treatment she had an accentuation of her symptoms -more difficulty in swallowing, chewing, talking, and an increase in her extremity weakness. She became apnoeic and on a few occasions required respiratory assistance. Her ACTH treatment was complicated by cystitis and thrombophlebitis. On 6 August 1967 she began improving, and by 9 August she had minimal ocular paresis and no facial weakness. Deglutition and speech were normal. She could chew solid food and could eat all of her meals without difficulty. There was no weakness of the neck muscles. She could walk in the hospital corridors without fatigue. This remission continued until at least the first week of October 1967. A neurological examination during September was entirely normal except for impaired conjugate gaze to the right; there was no specific ocular muscle paresis. She still gave a history of decreased exercise tolerance. She was not given maintenance therapy and did not continue in our care. According to her local physician she then became weaker during October and did not respond to increased dosage of anticholinesterase medication. As a last resort he hospitalized her in December 1967 and began treating her with 100 u. ACTH intramuscularly daily. On the fifth day of treatment she became unresponsive, and she died on the sixth day. Necropsy was not permitted.
In summary, this elderly lady was completely disabled by myasthenia in spite of anticholinesterase medication. Intensive ACTH therapy produced a two-month remission. She was not given maintenance therapy. On a second trial of intensive ACTH therapy she suddenly grew worse and died.
RESULTS
A diagnosis of myasthenia gravis was definitely established in all of the patients by the classical history and physical findings, by the improvement in strength after anticholinesterase medication, and/ or by the decline in amplitude of muscle action potentials after repetitive nerve stimulation. All of the patients had moderate to severe myasthenia that could not be adequately controlled with anticholinesterase medication. Two of the patients had thymectomies followed by brief remissions. This had no apparent influence on the ACTH therapy.
Corticotropin therapy resulted in significant improvement in all of our patients (Table II) . One (Grob and Namba, 1966 Torda and Wolff (1944a, b, c) suggested that ACTH augments the synthesis of acetylcholine and that the sera, cerebrospinal fluid, and thymic tissue from myasthenic patients inhibit acetylcholine synthesis. They believed there was a great enough relationship between ACTH and myasthenia gravis to warrant a clinical trial. They administered 400 mg ACTH over five days to five patients with myasthenia gravis (Torda and Wolff, 1949) . There was an initial worsening of the myasthenia until the second day after the treatment, at which time the patients began improving. An incomplete remission continued for three months. In 1951, the same authors reported the results of 15 patients treated with ACTH (500 mg over five days). A significant improvement occurred in 10 patients, no improvement occurred in four patients, and one patient died. They obtained more improvement in some patients with a second and a third series of ACTH. Millikan and Eaton (1951) This has necessitated repeated courses in some patients. Osserman and Genkins (1966) have used maintenance therapy in one elderly male for six months. This patient received an intensive course of therapy followed in one week by a second intensive course of ACTH. Clinical improvement was maintained by weekly or bi-weekly injections of ACTH. The follow-up was too brief to conclude that the maintenance injections actually prolonged the remission that he would have received from the two intensive courses. We have treated three patients with 100 u. ACTH intramuscularly every one to two weeks. Two patients have maintained their remissions for 16 and 20 months after an intensive course of ACTH. The other patient's (case 1) weakness had partially recurred before maintenance therapy was initiated. Clinical improvement was induced by weekly injections of ACTH and has been maintained for 23 months. In spite of these encouraging results, the duration of maintenance therapy has been too brief to warrant any firm conclusion.
In conclusion, we want to emphasize the necessity of careful patient selection, of using adequate doses of ACTH, and of 'compulsive' supervision of the patients in intensive medical care units during the treatment. Deviation from these guidelines will result in either poor results or death. In addition, we wish to call attention to the possibility that 'remissions' may be prolonged by maintenance therapy with ACTH injected weekly or less often.
SUMMARY
Five patients with myasthenia gravis have been treated with brief, massive doses of ACTH and three of these patients have also been given maintenance therapy. A significant improvement occurred after intensive ACTH therapy in all patients, but the benefit lasted an average of only 57 days. Maintenance therapy has prolonged the improvement, but the duration of treatment has been brief. 
